A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Daewoong Pharmaceutical Co. LTD. · Obesity & Overweight · Type 2 Diabetes
Phase 1
Recruiting
72
2026-07
Industry sponsor intelligence
Daewoong Pharmaceutical Co. LTD.Clinical Pipeline.
Lead-sponsor view of Daewoong Pharmaceutical Co. LTD.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 72
Pipeline overview
Programs by phase and activity.
Velocity
Daewoong Pharmaceutical Co. LTD. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 11
Phase 20
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Semaglutide → | 1 | 1 | 0 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Daewoong Pharmaceutical Co. LTD. studies.
This page groups studies where Daewoong Pharmaceutical Co. LTD. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first